<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647344</url>
  </required_header>
  <id_info>
    <org_study_id>AK104-207</org_study_id>
    <nct_id>NCT04647344</nct_id>
  </id_info>
  <brief_title>A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer</brief_title>
  <official_title>An Open-label, Multicenter, Phase Ib/II Study of AK104, Combined Chemotherapy as First-line Therapy to Treat Locally Advanced or Metastatic Non-small Cell Lung Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib/II , open-label, multicenter single arm study designed to evaluate the&#xD;
      efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 combined&#xD;
      with Carboplatin and Pemetrexed/ Paclitaxel as first-line therapy in patients with locally&#xD;
      advanced or metastatic non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">April 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 8, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing adverse events (AEs) (Phase Ib)</measure>
    <time_frame>From the time of informed consent through 90 days following termination of treatment with investigational product</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) assessed by investigator</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed concentration (Cmin) of AK104 at steady state</measure>
    <time_frame>From first dose of AK104 through 90 days after last dose of AK104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK104 through 90 days after last dose of AK104</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV</condition>
  <arm_group>
    <arm_group_label>Nonsquamous NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Squamous NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK104 plus Carboplatin and Pemetrexed</intervention_name>
    <description>Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
    <arm_group_label>Nonsquamous NSCLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK104 plus Carboplatin and paclitaxel</intervention_name>
    <description>Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.</description>
    <arm_group_label>Squamous NSCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent form voluntarily.&#xD;
&#xD;
          -  Age over 18 years old (inclusive) and not more than 75 years old (inclusive), when&#xD;
             signing the informed consent form.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.&#xD;
&#xD;
          -  Expected life expectance ≥ 3 months.&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of locally advanced or metastatic&#xD;
             NSCLC.&#xD;
&#xD;
          -  No prior systemic chemotherapy for advanced or metastatic NSCLC. Subjects who have&#xD;
             received prior adjuvant chemotherapy or neoadjuvant chemotherapy with curative intent,&#xD;
             or definitive chemoradiotherapy for advanced disease, will be eligible provided that&#xD;
             progression has occurred &gt;6 months from last treatment.&#xD;
&#xD;
          -  At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously&#xD;
             irradiated will not be considered a target lesion.&#xD;
&#xD;
          -  Subjects must provide an available tumor tissue sample taken &lt; 1 year prior to first&#xD;
             dose of study treatment.&#xD;
&#xD;
          -  Subjects must provide wild-type epidermal growth factor receptor (EGFR) and anaplastic&#xD;
             lymphoma kinase (ALK) reported by tissue-based tests（for non-squamous NSCLC subjects&#xD;
             only）.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active with a nonsterilized male&#xD;
             partner must use at least one highly effective method of contraception.&#xD;
&#xD;
          -  nonsterilized males who are sexually active with a female partner of childbearing&#xD;
             potential must use highly effective method of contraception from Day 1 and for 120&#xD;
             days after the last dose of investigational product.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are diagnosed as NSCLC that harbors an epidermal growth factor receptor&#xD;
             (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation.&#xD;
&#xD;
          -  Mixed tumors will be categorized by the predominant cell type; if small cell elements&#xD;
             are present, the subject is ineligible&#xD;
&#xD;
          -  Received prior treatment with EGFR inhibitors or ALK inhibitors.&#xD;
&#xD;
          -  Is currently participating intervention study or has participated in a study of an&#xD;
             investigational agent or investigational device within 4 weeks prior to administration&#xD;
             of AK104.&#xD;
&#xD;
          -  Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other&#xD;
             antibody or drug therapy for T cell co-stimulatory or checkpoint pathways, such as&#xD;
             Inducible T-cell co-stimulator (ICOS) or agonists (e.g. CD40, CD137, GITR and OX40&#xD;
             etc).&#xD;
&#xD;
          -  Subjects who received non-thoracic radiotherapy &gt;30 Gy within 4 weeks prior to the&#xD;
             first dose , or thoracic radiotherapy &gt;30 Gy within 24 weeks prior to the first dose&#xD;
             study drug.&#xD;
&#xD;
          -  Other active malignancies within 2 years, except for locally treatable (manifested as&#xD;
             cured) malignancies, such as basal or skin squamous cell carcinoma, superficial&#xD;
             bladder cancer, cervical or breast carcinoma in situ.&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease, or a medical history of&#xD;
             autoimmune disease,&#xD;
&#xD;
          -  Subjects who require systemic corticosteroids (a dose equivalent to &gt;10 mg/day&#xD;
             prednisone) or other immunosuppressive drugs within 14 days prior to administration of&#xD;
             AK104.&#xD;
&#xD;
          -  Known history of allogeneic organ transplantation or allogeneic hematopoietic stem&#xD;
             cell transplantation.&#xD;
&#xD;
          -  Active or previously documented inflammatory bowel disease (e.g. Crohn's disease,&#xD;
             ulcerative colitis or chronic diarrhea).&#xD;
&#xD;
          -  Has interstitial lung disease or a history of pneumonitis that required oral or&#xD;
             intravenous glucocorticoids to assist with management.&#xD;
&#xD;
          -  Known history of active tuberculosis (TB).&#xD;
&#xD;
          -  An active infection requiring systemic therapy.&#xD;
&#xD;
          -  Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA&#xD;
             exceeding 1000 IU/ mL or active hepatitis C virus (HCV) should be excluded. Subjects&#xD;
             with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA &lt;1000 IU/ mL)&#xD;
             , and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are&#xD;
             eligible only if the HCV RNA test results are negative.&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Presence of meningeal metastasis, spinal cord compression, leptomeningeal disease or&#xD;
             active brain metastasis.&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated&#xD;
             drainage.&#xD;
&#xD;
          -  Unresolved toxicities from prior anticancer therapy, defined as having not resolved to&#xD;
             NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion&#xD;
             criteria, with the exception of alopecia.&#xD;
&#xD;
          -  Receipt of live vaccination within 30 days of planned treatment start, or plan to&#xD;
             receive live vaccine during the study.&#xD;
&#xD;
          -  Known history of server hypersensitivity to other monoclonal antibodies.&#xD;
&#xD;
          -  Known severe allergic reactions to pemetrexed, paclitaxel, carboplatin or&#xD;
             platinum-containing component, or their preventive medications.&#xD;
&#xD;
          -  Known allergic reactions to any ingredients of AK104.&#xD;
&#xD;
          -  Known history of substance abuse, or alcohol abuse&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Any conditions that, in the investigator's opinion, may put subjects treated with the&#xD;
             study drug at risks, or interfere with the evaluation of study drug or subject safety,&#xD;
             or the interpretation of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoping Jin, PhD</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 21, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

